A Phase 2 interventional study of benralizumab and benralizumab in Eosinophilic Chronic Rhinosinusitis, sponsored by Kyowa Kirin Co., Ltd.. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-04-23.
Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this study is to evaluate the efficacy and safety of SC administrations of Benralizumab or Placebo in the subjects with Eosinophilic Chronic Rhinosinusitis in a multicenter, randomized, double-blind, placebo-controlled study. The pharmacokinetics and immunogenicity will be assessed secondarily.
Screening Period (maximum 4 weeks) , Randomized Treatment Period (24 weeks)
251 studies on the registry are indexed under Rhinosinusitis; 69 are open to participants now.
This study's enrollment of 63 is below the median of 74 across 177 interventional studies indexed under Rhinosinusitis.
Browse Rhinosinusitis studies →Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subcutaneous (SC) administration
Drug: benralizumab
SC administration
Drug: benralizumab
Placebo SC administration
Drug: Placebo
SC administration
SC administration
SC administration
The change from baseline in nasal polyp score at Week 12
Time frame: baseline and 12 weeks post-dose
The change from baseline in nasal polyp score
Time frame: Pre-dose and 4,8,12,16,20,24 weeks post-dose
The change from baseline in Computed tomography (CT) score
Time frame: baseline and 12 weeks post-dose
Number of subjects discontinued from the study due to aggravation of eosinophilic chronic rhinosinusitis
Time frame: Up to 24 weeks after dosing
Time to discontinuation (days) from the study due to aggravation of eosinophilic chronic rhinosinusitis
Time frame: Up to 24 weeks after dosing
The change from baseline in Blood eosinophil count
Time frame: Pre-dose and 4,8,12,16,20,24 weeks post-dose
The change from baseline in Nasal Airway Resistance
Nasal airway resistance (Pa/cm\^3/s)
Time frame: Pre-dose and 4,8,12,24 weeks post-dose
The change from baseline in the averaged values of the Olfactory thresholds
Olfactory thresholds are assessed by T\&T Olfactometer Test Score (Five kinds of smell with eight (5 to -2) phases).
Time frame: Pre-dose and 4,8,12,24 weeks post-dose
The change from baseline in the improvement of olfactory dysfunction
Olfactory dysfunction (1 to 5) is calculated by the Olfactory thresholds.
Time frame: Pre-dose and 4,8,12,24 weeks post-dose
The change from baseline in Sino-Nasal Outcome Test-2 (SNOT-22)
Symptom score are assessed by VAS (nasal congestion, anterior and posterior nasal drip, loss of the sense of smell, headache, and impairment in activity of daily living)
Time frame: Pre-dose and 4,8,12, 16, 20, 24 weeks post-dose
The change from baseline in Symptom score by Visual Analog Scale (VAS)
Symptom score are assessed by VAS (nasal congestion, anterior and posterior nasal drip, loss of the sense of smell, headache, and impairment in activity of daily living)
Time frame: Pre-dose and 4,8,12, 16, 20, 24 weeks post-dose
Incidence of treatment-emergent adverse events (TEAEs) or drug-related TEAEs and their nature
Time frame: Up to 24 weeks after dosing
Serum concentration of benralizumab
Time frame: Pre-dose and 4, 8, 12, 16, 20, 24 days post-dose
Plan to share: No
Ran from Jun 2016 to primary completion in Mar 2017, 9 months.
Of 16 phase 2 interventional studies under Rhinosinusitis, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 26. This study's 9 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab